⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
HELP News
Cybin Inc. Common Stock
Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder
globenewswire.com
HELP
Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments
prnewswire.com
GHRS
DFTX
HELP
ATAI
LBRX
Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders
prnewswire.com
HELP
AXSM
RLMD
ANRO
CMPS
Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity
prnewswire.com
HELP
TAK
BMY
PFE
CMPS
Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee
globenewswire.com
HELP
Nature Medicine Publishes Helus Pharma’s Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder
globenewswire.com
HELP
HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights
globenewswire.com
HELP
Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market
prnewswire.com
HELP
TAK
AZN
JNJ
ABBV
Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and Execution
globenewswire.com
HELP